A number of industry policies were released, and the amount of license out transactions hit a new high [Three-minute quick overview of one week's medical highlights]

The State Administration for Market Regulation issued the "Administrative Measures for the Supervision and Administration of the Production and Operation of Cosmetics"; "Long-term Prescription Management Regulations (Trial)", "Guiding Principles for Research on Immunogenicity of Low Molecular Weight Heparin Generic Drugs (Trial)" and other documents issued.

Industry·Policy News

1.

2.

3.

4.

5.

Product development and listing information

1.

2.

3.

4.

5.

6.

7.

Pharmaceutical Industry Observation

1.

2.

3.

4.
Hutchison Medicine and Epizyme announced their cooperation
.
According to the agreement, Hutchison Pharmaceuticals will obtain the development and commercialization rights of the anti-cancer drug Tazverik (tazemetostat) developed by the latter in the Greater China region.
Epizyme will receive a down payment of US$25 million and a potential milestone payment of no more than US$285 million.
, And additional royalties
.

5.
Deqi Pharmaceuticals and AI drug research and development company De Rui Zhiyao announced that the two companies have reached a long-term strategic cooperation to jointly promote the research and development of small molecule anti-tumor first-in-class drugs
.

6.
British Silicon Intelligence and Yousen Jianheng announced that they have reached a strategic cooperation
.
According to the agreement, the two parties will focus on unmet clinical needs in areas such as cancer and autoimmune diseases, combining the advantages of British Silicon’s end-to-end artificial intelligence drug discovery platform and the experience in the research and development of small molecule innovative drugs by Usenjianheng, and explore new Target discovery and druggability research, carry out compound screening, design and synthesis for difficult drug targets, and accelerate the development of small molecule innovative drugs
.

7.
Junshi Pharmaceutical issued an announcement stating that the company's product teriprizumab combined with gemcitabine/cisplatin was recognized as a breakthrough therapy by the US FDA as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal cancer
.

8.
Renfu Pharmaceutical issued an announcement stating that the company's product, venlafaxine hydrochloride sustained-release capsules, has obtained the US FDA approval number
.

9.
Jingtai Technology announced the completion of US$400 million in Series D financing.
This round of financing was led by Hopu Capital and Aobo Capital, followed by China Biopharmaceutical Group and other institutions, and early shareholders such as Tencent Group, Sequoia Capital and Wuyuan Capital continued.
Additional investment
.
After this financing investment, the company's valuation exceeded 13 billion yuan
.

10.
Chengdu Jiabao Yaoyin Pharmaceutical Technology Co.
, Ltd.
announced that the company has completed a 100 million yuan Pre-A round of financing
.
This round of financing was led by Dingxiang Capital, followed by Probe Capital.
The financing funds will be used to promote the clinical development of pipeline drugs, improve the R&D team and expand the pipeline globally
.

11.
Zhao Derivatives announced that it has completed 150 million US dollars in Series B financing, led by CPE Yuanfeng, and Songhe Capital, Hongtai Fund, Yingke Capital and other institutions jointly participated in the investment
.
This financing funds will be mainly used for the construction of Zhao Derivatives' R&D and production centers in Beijing and Chongqing, and the expansion of production facilities in California, USA.
The company's global CDMO service production capacity layout has accelerated again
.

Centralized procurement of medical equipment

1.
The Public Resources Trading Center of Liaoning Province issued the "Notice on the Result of the Active Price Reduction of 368 Drugs including Lovastatin Capsules"
.
The average drop of these 368 drugs was 8%, and the highest drop was 63%
.
All medical and health institutions in the province will implement the new online purchase price from 0:00 on August 10
.

2.
Guangdong Drug Trade Center issued a notice on supplementary solicitation of some clauses in the "Amoxicillin and other 45 drug alliance regional groups with a large amount of procurement documents (draft for comments)", and added 6 clauses on the basis of the original solicitation of drafts.
But the plan to be allocated is still not completely clear
.

3.
Shanghai Sunshine Pharmaceutical Procurement Network issued the "Notice on Announcement of the Online Purchase of the Sixth Batch of Bargained Drugs (Self-paid Drugs) in 2021", and published a detailed list of the sixth batch of bargained drugs (self-paid drugs) in 2021, including 72 Varieties, involving 56 pharmaceutical companies
.

4.
Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Procurement Center issued the "Notice on Carrying out the Online Procurement of Chemical Drugs on the Standardized Platform (Draft for Solicitation of Comments)", and will carry out the online procurement of chemical drugs on the standardized platform
.
The online categories are divided into direct online catalogs and alternative drugs online catalogs.
The scope of online drugs includes the completion of the new round of inter-provincial linkage of platform drug catalogs, and the current procurement of chemical drugs on the new platform in Shanxi Province
.

5.
Hunan Province issued a letter on soliciting opinions on the "Implementation Plan for the Renewal of the Concentrated Procurement of Antibacterial Drugs in Hunan Province in 2021 (Draft for Solicitation of Comments)", requesting feedback before August 13
.

6.
The Hubei Province Pharmaceutical Price and Bidding Procurement Management Service Network issued the "Notice on Publicizing Hubei Province’s First Batch of Drug Centralized Purchases of Non-selected Varieties on the Internet and the Results of the Drafting of Medical Insurance Payment Standards
.
" According to the attachment, the latest online prices of 300 drugs were disclosed.
At the same time, the medical insurance payment standards for 270 drugs and 361 drugs whose online price adjustments were not reported as required were suspended
.